Treatment of chronic lymphocytic leukaemia in three dogs with melphalan and prednisolone
Treatment of chronic lymphocytic leukaemia in three dogs with melphalan and prednisolone
复制标题
DOI：
10.1111/j.1748-5827.2004.tb00239.x
复制
发表时间：
2004-06-01
影响因子：
1.6
通讯作者：
Tsujimoto, H
中科院分区：
文献类型：
--
作者：
Fujino, Y;Sawamura, S;Tsujimoto, H
用马法兰和泼尼松龙成功地治疗了三只患有慢性淋巴细胞白血病（CLL）的成年狗。基于白血病细胞的免疫表型分析，两只狗被诊断为B细胞CLL，一只狗被初步诊断为T细胞CLL。1只患有B细胞CLL的犬出现IgM单克隆丙种球蛋白病。给予马法仑（3 - 5 mg/m2/天）和泼尼松龙（4-3 - 30 mg/m2/天）8 - 210天后，3只犬中与CLL相关的临床体征和血液学异常得到改善。除血浆碱性磷酸酶活性轻度升高外，无严重不良反应。马法兰和泼尼松龙治疗可以达到缓解与CLL狗的副作用少。
Three adult dogs with chronic lymphocytic leukaemia (CLL) were successfully treated with melphalan and prednisolone. Based on the immunophenotypic analysis of leukaemic cells, two dogs were diagnosed with B cell CLL and one dog was tentatively diagnosed as having T cell CLL. One dog with B cell CLL had IgM monoclonal gammopathy. The clinical signs and haematological abnormalities associated with CLL in the three dogs improved with the administration of cytoreductive melphalan (3 to 5 mg/m(2)/day) and prednisolone (4-3 to 30 mg/m(2)/day) for eight to 210 days. There were no severe adverse effects except a mild increase in plasma alkaline phosphatase activity. Melphalan and prednisolone therapy may achieve remission with few side effects in dogs with CLL.